At the end of last century,the snlall-molecule selective kinase inhibitor,imatinib mesylate (IM),Was successfully exploited.This resulted in a revolutionary step in the treatment of chronic myeloid leukemia(CML).However,along with the expansion of its clinical application and the process,drug resistance Was commonly observed in patients, especially during accelerated or blast phases, and has become a significant therapeutic problem in clinical application.The problem has prompted the appearance of novel small molecule tyrosine kinase inhibitors,and its development is reviewed.

Cancer stem cells comprise a sub-population with the capacity of self-renewal,self-differentiation and high tumorigenicity.Cancerogenesis,development,relapse and therapeutic resistance are closely related with these cells.The most important characteristics of these cells are the ability to self-renew.So insight into the regulating mechanism of self-renewal in cancer stem cells will be important for the development of novel molecular agents targeted the cancer stem cells.

Serine/ aginine rich(SR)protein,SR protein kinase and other enzymes participate in the composition of alternatively spliced tissue factor(asTF). Recently researchers have found that this protein takes a part in tumor angiogenesis,tumor progression,metastasis and so on,so the detection of its clinical content will be very significant.

Objective To discuss the observation and nursing of adverse reactions in chronic myelocytic leukemia patients receiving imatinib therapy.Methods Adverse reactions were observed and recorded in 193 chronic phase myelocytic leukemia patients who received imatinib therapy,and corresponding treatment and nursing were given to them.Results Among 193 patients,more than 60％ of patients had adverse reactions,of which,54％ of patients showed gastrointestinal adverse reactions including nausea,vomiting,anepithymia and diarrhea; 22％ of them had muscle and bone pain; 7％ had rash; 65％ got edema.After proper treatment and nursing,all adverse effects obtained satisfactory remission.Condusions During the treatment course of chronic myelocytic leukemia patients using imatinib,careful observation of any possible adverse reactions,and giving corresponding treatment and nursing can facilitate good compliance and longterm remission of patients.

Aim To apply simple combined models to screen small molecule BDNF-like compounds for potential pharmacotherapy of central nerve degenerative diseases.Methods BDNF-like bioactivities were dentified with effects against apoptosis induced by serum withdrawal in turn in cultured human SH-SY5y cells,rat NIH3T3/trkB cells vs NIH3T3 cells,using MTT technique.Results More than 400 compounds were tested by using these methods.11 of them presented protective effects on apoptosis induced by serum withdrawal in SH-SY5y cells.2 of them also provided selective protection against apoptosis induced in NIH3T3/trkB cells versus in NIH3T3 cells,which were identified as BDNF-like compounds.Further study showed that these 2 compounds could withstand SH-SY5y cell injuries induced by 6-OHDA.Conclusion All the above studies provide a useful series of simple models for BDNF-like drug screen and some compound candidates for further study of neuroprotection.

Abdominal Neoplasms ; etiology ; genetics ; Adolescent ; Chromosome Aberrations ; Humans ; Karyotyping ; Leukemia, Myeloid, Acute ; complications ; genetics ; Male ; Sarcoma, Myeloid ; etiology ; genetics

Objective:To study expressions of CD117 and CD34 in the patients with acute promyelocytic leukemia(APL,M3) and in M1-M2 subtype from FAB classification for acute leukemia(AL).The focus of the study would be laid on the clinical significance of CD117/CD34 co-expression in the patients of M3 subtype.Methods:Researched cases of acute nonlymphoblastic leukemia(ANLL) were divided into two groups:M1-M2 subtype and M3 subtype.Flow cytometery(FCM) was used to detect the rates of positive expression of CD117 and CD34 on bone marrow mononuclear cell(BMMNC) in 54 patients of M3 and 63 patients of M1-M2 subtype respectively.Meanwhile,we compared the differences between the rates of expression of CD117 and CD 34.And,the rates of CD117/CD34 co-expression in patients of M1-M2 subtype and M3 subtype were studied.Results:Our results revealed that the positive rates of CD117 expression in M1-M2 subtype and M3 subtype were 71.4%(45/63) and 66.7%(36/54) respectively(P=0.58).The positive rates of CD34 expression in M1-M2 subtype and M3 subtype were 66.7%(42/63) and 11.1%(6/54) respectively(P=0.000).The positive rates of CD117/CD34 co-expression in M1-M2 subtype and M3 subtype were 71.1%(45/63) and 7.4%(4/54) respectively(P=0.000).Conclusion:CD117 may be used as immunology marker for leukemia of myeloid origin.CD34 had lower expression in M3 subtype than in M1-M2 subtype.The positive rate of CD117/CD34 co-expression in M3 subtype was significantly lower than that in M1-M2 subtype,which can help for diagnosis of M3 subtype and help differentiate M3 subtype from M1-M2 subtype as well.

Adult ; Boronic Acids ; therapeutic use ; Bortezomib ; Combined Modality Therapy ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; POEMS Syndrome ; therapy ; Pyrazines ; therapeutic use

BACKGROUND: With the optimization of transplantation scheme and the emergence of graft-versus-host disease (GVHD) therapy drugs, allogeneic hematopoietic stem cell transplantation (allo-HSCT) in recent years has made great progress that makes patients with hematological malignancies have more long-term survival opportunities. OBJECTIVE: To compare the efficiency and safety of three types of allo-HSCT used in the treatment of adults with Philadelphia chromosome (Ph) in acute lymphoblastic leukemia (Ph+ALL).METHODS: A total of 69 patients with Ph+ALL who received allo-HSCT from June 2006 to November 2013 were enrolled, including 23 cases of sib-matched donor transplantation, 24 cases of unrelated-matched donor transplantation, and 22 cases of haploidentical donor transplantation. There were 54 cases of CR1, 13 cases of CR2 to CR3 and 3 cases of relapse. The bone marrow or/and peripheral blood stem cells were used for transplantation. All patients were subjected to pretreatment consisting of cytarabine, busulfan, cyclophosphamide and total body irradiation. GVHD was prevented by combined use of immunosuppressants including cyclosporine A, short-term methotrexate, mycophenolate mofetil and anti-human thymocyte globulin, etc.RESULTS AND CONCLUSION: The results showed that 68 patients acquired hematopoietic reconstitution, and only 1 case of haploidentical donor transplantation failed. The mean follow-up period was 20.4 months. The acute GVHD incidence of the sibling matched-HSCT, unrelated donor HSCT and related haploidentical allo-HSCT was 30％, 33％ and 45％,respectively; the chronic GVHD incidence (cGVHD) incidence was 22％, 29％ and 36％, respectively; the incidence of aGVHD and cGVHD between groups showed no statistically significant difference. Transplant related mortality (TRM) was 9％, 29％ and 41％, respectively, and there was a significant difference among groups (0.01 < P < 0.05). Recurrence rates were 17％, 21％ and 14％, respectively, and there was no significant difference among groups. The 3-year overall survival rates were 68％, 49％ and 43％, respectively; there were significant differences between sib-matched-HSCT and the other two groups, but no statistically significant difference was found between unrelated donor HSCT and related haploidentical allo-HSCT groups. The 3-year overall survival rate was 58％ for 54 patients in CR1 and 41％ for 15 patients in non-CR1 states. To conclude, the sib-matched HSCT has better effect than unrelated donor transplantation and related haploidentical allo-HSCT; Ph+ALL patients should do transplantation as early as possible in the state of CR1.

Purpose:To explore the expression of human c kit receptor protein (c kit R, CD117) in acute leukemia (AL). The focus of the study was put on the value of the expression of c kit R in diagnosis for acute non lymphoid leukemia (ANLL).Methods:Flow cytometry (FCM) was used to determine the expression of the transmembrane c kit R on mononeuclear cell in bone marrow in 24 patients with acute lymphoid leukemia (ALL) and 47 patients with acute non lymphoid leukemia (ANLL). Results:There was no significant difference between expression of c kit in healthy individuals and patients with ALL. The expression of c kit in patients with ANLL was significantly higher than that of healthy individuals and that of patients with ALL ( P